Capricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Above Fifty Day Moving Average of $5.56

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $5.56 and traded as high as $5.65. Capricor Therapeutics shares last traded at $5.04, with a volume of 912,876 shares.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on CAPR shares. StockNews.com raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 24th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Friday, March 1st. Finally, Cantor Fitzgerald began coverage on shares of Capricor Therapeutics in a research report on Friday, January 5th. They set an “overweight” rating and a $8.00 price target for the company.

Capricor Therapeutics Trading Up 4.6 %

The stock has a 50-day moving average price of $5.56 and a two-hundred day moving average price of $4.34. The stock has a market cap of $158.78 million, a price-to-earnings ratio of -5.79 and a beta of 3.99.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.21. Capricor Therapeutics had a negative return on equity of 299.67% and a negative net margin of 88.52%. The business had revenue of $12.09 million during the quarter, compared to the consensus estimate of $5.80 million. Research analysts predict that Capricor Therapeutics Inc will post -0.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capricor Therapeutics stock. Jump Financial LLC acquired a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 52,800 shares of the biotechnology company’s stock, valued at approximately $258,000. Jump Financial LLC owned about 0.17% of Capricor Therapeutics at the end of the most recent reporting period. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.